Bioavailability enhancement of sulpiride by self-microemulsifying drug delivery system
The self-microemulsifying drug delivery system (SMEDDS) was employed to improve the bioavailability of sulpiride, a drug which is poorly soluble. The mean droplet size and emulsification time of the test formulation used for in vivo study were 9.27 ± 2.02 nm and 87 ± 5 s, respectively. When compar...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Articulo |
| Lenguaje: | Inglés |
| Publicado: |
2010
|
| Materias: | |
| Acceso en línea: | http://sedici.unlp.edu.ar/handle/10915/7941 http://www.latamjpharm.org/resumenes/29/4/LAJOP_29_4_1_4.pdf |
| Aporte de: |
| Sumario: | The self-microemulsifying drug delivery system (SMEDDS) was employed to improve the
bioavailability of sulpiride, a drug which is poorly soluble. The mean droplet size and emulsification time
of the test formulation used for in vivo study were 9.27 ± 2.02 nm and 87 ± 5 s, respectively. When compared
with Reference (Dogmatil®), the test formulation exhibited faster in-vitro drug release rate. The
Cmax and AUC values of the test formulation were significantly higher than those of Reference, with an
enhancement of 210.64% in the extent of absorption in rabbits. In conclusion, SMEDDS could be a potential
drug delivery system to enhance the bioavailability of sulpiride. |
|---|